AstraZeneca and Daiichi Sankyo Advance Enhertu in Tumour-Agnostic Oncology
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the European Medicines Agency’s Committee for...
CHMP Opinion
Advertisement
Gilead Expands Oncology Portfolio With Tubulis Deal
Foster City, California, USA – May 22, 2026 Gilead Sciences, Inc. announced the successful completion of its acquisition of...
Astellas’ PADCEV Combo Wins CHMP Support in MIBC
Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...
Allergan’s Boey Moves Closer to EU Approval for Glabellar Lines
North Chicago, Illinois, USA – May 21, 2026 Allergan Aesthetics, an AbbVie company and global leader in medical aesthetics,...
AbbVie Reports Strong Phase 3 Results for MAVIRET in Acute HCV
North Chicago, Illinois, USA – May 22, 2026 AbbVie announced that the European Medicines Agency’s Committee for Medicinal Products...
Advertisements
Boehringer Ingelheim Strengthens Fibrosis Portfolio With JASCAYD
Ingelheim, Germany – May 22, 2026 Boehringer Ingelheim announced that the European Medicines Agency’s Committee for Medicinal Products for...
Santhera Pharmaceuticals Gains EU Boost for AGAMREE Expansion
PRATTELN, Switzerland, April 27, 2026 Santhera Pharmaceuticals has achieved a significant regulatory milestone with the European Medicines Agency’s (EMA)...
Pharming’s Joenja Wins CHMP Nod for APDS in EU
LEIDEN, Netherlands, March 27, 2026 Pharming Group N.V. announced that the Committee for Medicinal Products for Human Use (CHMP)...
IMCIVREE Gains EU Momentum for Rare Obesity Disorder
Boston, March 26, 2026 In a significant advancement for rare disease therapeutics, Rhythm Pharmaceuticals has received a positive opinion...
CHMP Endorses Monthly Elfabrio Dosing for Fabry Disease
PARMA, Italy and CARMIEL, Israel, Jan. 30, 2026 — Chiesi Global Rare Diseases and Protalix BioTherapeutics announced that the...
Advertisement
